CLDX logo

Celldex Therapeutics, Inc

CLDX

CLDX: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

more

Show CLDX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CLDX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CLDX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs Oct. 04, 2022
  • Patent Title: Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs May. 17, 2022
  • Patent Title: Antibodies that bind human cd27 and uses thereof Nov. 23, 2021
  • Patent Title: Anti-alk antibodies and methods for use thereof Aug. 17, 2021
  • Patent Title: Methods of inducing or enhancing an immune response comprising administering agonistic anti-cd40 antibodies Mar. 09, 2021
  • Patent Title: Nucleic acids encoding agonistic antibodies that bind cd40 Dec. 15, 2020
  • Patent Title: Methods of treating by administering anti-kit antibodies Oct. 06, 2020
  • Patent Title: Methods of treating by administering anti-kit antibodies Sep. 22, 2020
  • Patent Title: Treatment of eosinophil or mast cell related disorders Sep. 15, 2020
  • Patent Title: Anti-erbb antibodies and methods of use thereof Aug. 18, 2020
  • Patent Title: Treatment of eosinophil or mast cell related disorders Mar. 26, 2019
  • Patent Title: Polynucleotides encoding anti-kit antibodies Jan. 29, 2019
  • Patent Title: Methods of treating a kit-associated cancer by administering anti-kit antibodies Jan. 22, 2019
  • Patent Title: Treatment of chronic nephropathies using soluble complement receptor type i (scr1) May. 16, 2017
  • Patent Title: Method of improving transplant function using soluble complement receptor type i (scr1) May. 16, 2017
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Apr. 18, 2017
  • Patent Title: Polynucleotides encoding anti-kit antibodies Mar. 28, 2017
  • Patent Title: Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof Feb. 28, 2017
  • Patent Title: Treatment of chronic nephropathies using soluble complement receptor type i (scr1) Mar. 29, 2016
  • Patent Title: Antibody vaccine conjugates and uses therefor Feb. 16, 2016
  • Patent Title: Antibody vaccine conjugates and uses therefor Jan. 26, 2016
  • Patent Title: Antibodies that bind human cd27 and uses thereof Oct. 27, 2015
  • Patent Title: Monoclonal antibodies to dendritic cells Aug. 04, 2015
  • Patent Title: Method of detecting and treating tuberous sclerosis complex associated disorders Jun. 09, 2015
  • Patent Title: Antibodies directed to gpnmb and uses thereof Sep. 30, 2014
  • Patent Title: Treatment for age-related macular degeneration and other diseases of the eye Mar. 04, 2014
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Nov. 19, 2013
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Jan. 29, 2013
  • Patent Title: Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (mcsp) Nov. 27, 2012
  • Patent Title: Antibodies that bind human dendritic and epithelial cell 205 (dec-205) Aug. 07, 2012
  • Patent Title: Method for enhancing t cell reactivity toward tumour antigens Mar. 16, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CLDX in WallStreetBets Daily Discussion

CLDX News

Recent insights relating to CLDX

CNBC Recommendations

Recent picks made for CLDX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CLDX

Corporate Flights

Flights by private jets registered to CLDX